Market Size
Global Hemangioma Treatment Market reached USD 318.3 million in 2025 and is expected to reach USD 427.9 million by 2033 growing with a CAGR of 3.8% during the forecast period 2026-2033. Infantile hemangioma is the most commonly occurring benign vascular tumor among infants affecting about 4% to 5% of newborns.
The global hemangioma treatment market has witnessed significant growth in recent years due to the adoption of beta-blocker treatments. For instance, propranolol and atenolol are beta blockers that are commonly used as a treatment for infantile hemangiomas.
Furthermore, significant growth drivers such as increasing clinical trials, growing investments, and increasing research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Akorn Pharmaceuticals, Pfizer Inc., Alma Lasers Ltd., Allergan, and others are actively operating in the market.
Market Scope
| Metrics | Details |
| CAGR | 3.8% |
| Size Available for Years | 2025-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Type, Diagnosis, Treatment, End Users |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Others key Insights. |
Market Dynamics
Market Drivers
Rising Technological Advancements for Hemangioma Treatment
Hemangiomas are non-cancerous tumors where capillary blood vessels increase in number through the process of angiogenesis, and the major technological advancements from major companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for billions of people with hemangiomas.
For instance, in September 2020, Pierre Fabre Pharmaceuticals reported a new online tool for the early diagnosis and referral of infantile hemangioma that can help avoid complications stemming from delayed treatment. This study highlights the reliability and ease of use of the Infantile Hemangioma Referral Score (IHReS) for the early diagnosis, referral, and treatment of infantile hemangioma (IH). Thus, the above factors help to boost the market growth in the forecast period.
The Increasing Clinical Trials for Hemangioma Treatment
The rising clinical trials of hemangioma globally act as the driver to the growing demand for the hemangioma treatment market. For instance, according to ClinicalTrial.gov, on May 12, 2023, Indiana University conducted an interventional study on Natural Berry Extract Treatment of Hemangiomas. This is a prospective, randomized, double-blind, placebo-controlled parallel-group study.
The aim of this clinical trial is to evaluate the use of PediaBerry for the treatment of hemangiomas in infants less than 4 months of corrected gestation age over a 6-month treatment period. The treatment involves PediaBerry which will be mixed with a cream vehicle for topical administration or with water for oral administration.
Market Restraints
Complications Associated with Infantile Hemangiomas
Infantile hemangioma complications are classified as life-threatening, obstructive, and ulcerative. Life-threatening complications include airway and hepatic infantile hemangiomas. Functional complications obstructing vital structures or impairing function involve periocular, nasal, labial, parotid, auricular, and breast infantile hemangiomas. Thus, owing to the above factors the market is expected to hamper over the forecast period.
Segment Analysis
The global hemangioma treatment market is segmented based on type, diagnosis, treatment, end users, and region.
Laser Therapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Hemangioma Treatment Market Share
The rising clinical trials of hemangiomas globally have contributed to the growing demand for hemangioma treatment. Laser therapy involves the use of specific wavelengths of light to stimulate healing by allowing surgeons to work at high levels of precision by focusing on a small area by damaging less of the surrounding tissue. The main aim of performing laser therapy is to reduce inflammation and muscle pains.
For instance, according to clinicalTrials.gov, on August 12, 2022, Massachusetts General Hospital conducted a clinical trial on pulsed-dye laser versus timolol topical solution versus observation on the growth of hemangioma in newborn. The purpose of this study is to find out if pulsed dye laser treatment or timolol maleate 0.5% gel can help infants who have a hemangioma. Thus, the above factors help to elevate the market growth.
Geographical Penetration
North America Accounted for Approximately 38.9% of the Market Share in 2022
North America has maintained a significant proportion of the hemangioma market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as an increase in healthcare expenditures, increasing research and developments, and technological advancementsin hemangioma treatment.
For instance, according to the National Health Expenditure Account (NHEA), the total annual healthcare expenditure in the United States is increased by 2.7% to $4.3 trillion. Physician spending grew by an average of 3.5% per year while hospital services (4.4%) and clinical services (6.7%) had higher growth rates. Thus, the above factors help to elevate the region's growth.
Major Companies
The major global players in the market include Cutera Inc., Merck & Co., AbbVie Inc, Akorn Pharmaceuticals, Pfizer Inc., Alma Lasers Ltd., Allergan, Linline Medical Systems, Pierre Fabre, and IRIDEX Corporation among others.
By Type
- Capillary Hemangioma
- Cavernous Hemangioma
- Compound Hemangioma
- Lobular Capillary Hemangioma
By Diagnosis
- Ultrasound
- MRI
- CT Scan
- Others
By Treatment
- Medical Therapy
- Laser Therapy
- Surgery
- Beta Blocker Medicines
- Others
By End Users
- Hospitals
- Clinics
- Diagnostic Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Recent Developments
- May 2026: Pfizer Inc. expanded pediatric vascular-disorder research initiatives supporting advanced hemangioma treatment development, improved patient outcomes and long-term dermatology care solutions globally.
- April 2026: Pierre Fabre Group strengthened dermatology-treatment portfolios through enhanced topical-therapy development targeting infantile hemangioma management and vascular-lesion treatment advancements.
- March 2026: Novartis AG accelerated clinical research activities focused on targeted therapies and combination-treatment approaches for complex hemangioma and vascular-anomaly disorders.
- February 2026: American Academy of Dermatology expanded awareness initiatives supporting early diagnosis, multidisciplinary treatment adoption and improved clinical-management practices for infantile hemangioma patients.
- January 2026: LEO Pharma advanced pediatric dermatology research programs supporting innovative topical and non-invasive treatment solutions for superficial hemangioma conditions.
- December 2025: Galderma enhanced vascular-lesion treatment capabilities through investments in laser-based dermatology technologies and minimally invasive cosmetic-treatment advancements.
- November 2025: Candela Medical expanded pulsed-dye laser technology offerings supporting improved hemangioma lesion reduction, skin-rejuvenation outcomes and pediatric dermatology applications globally.
- October 2025: AbbVie Inc. strengthened biologics and immunology research programs supporting innovative therapeutic approaches for complex vascular and dermatologic disorders.
- September 2025: Bausch Health Companies Inc. increased investments in dermatology-treatment innovation supporting advanced topical formulations and vascular-anomaly management solutions worldwide.
- July 2025: Cutera Inc. enhanced laser-treatment technology integration supporting non-invasive hemangioma therapy, precision dermatology procedures and improved pediatric treatment safety standards.
Why Purchase the Report?
- To visualize the global hemangioma treatment market segmentation based on the type, diagnosis, treatment, end users, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global hemangioma treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global hemangioma treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
For more Lifesciences and Healthcare related reports, please click here
